**Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes – SCORE IT: Study protocol for the development of a core outcome set**

Dr Nicola L Harman PhD1\*, n.harman@liv.ac.uk

 Professor John Wilding DM FRCP2, jwilding@liv.ac.uk

Mr Dave Curry1, d.curry310@btinternet.com

Mr James Harris1, jim37@sky.com

Dr Jennifer Logue3 Jennifer.Logue@glasgow.ac.uk

Mr R. John Pemberton1 , jaypee55@sky.com

Dr Leigh Perreault 3,4 MD, Leigh.Perreault@ucdenver.edu

Mr Gareth Thompson1, garethbond007@gmail.com

Dr Sean Tunis5, sean.tunis@cmtpnet.org

Professor Paula R Williamson PhD 1  prw@liv.ac.uk

on behalf of the SCORE-IT study team.

1. Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, Liverpool, UK, L69 3GL
2. Obesity and Endocrinology Clinical Research Group, Institute of Ageing and Chronic Disease, University Hospital Aintree, Longmoor Lane, Liverpool, L9 7AL
3. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
4. Division of Endocrinology, Metabolism and Diabetes. Affiliate Center for Global Health

University of Colorado Anschutz Medical Campus. 13001 E. 17th Pl. Aurora, CO 80045

 Colorado School of Public Health, 13001 E. 17th Place, Mail Stop B119, Aurora, CO 80045

1. Center for Medical Technology Policy (CMTP), World Trade Center Baltimore, Baltimore, MD, United States of America.

\*corresponding author Nicola L Harman, n.harman@liv.ac.uk

**Abstract**

**Background:** Type 2 diabetes is characterised by abnormal glucose metabolism and treatment is aimed at normalising glycaemia. Outcomes measured in clinical trials should be meaningful to patients, health care professionals and researchers, yet there is heterogeneity in the outcomes used across trials of glucose lowering interventions. This inconsistency impacts on the ability to compare findings and may mean that the results have little importance to health care professionals and the patients that they care for. The SCORE-IT study aims to develop a core outcome set (COS) for use in all trials of glucose lowering interventions for people with type 2 diabetes.

**Methods/design:**  This study will involve three key stages in the development of a COS: 1) The identification of a list of outcomes from multiple sources, specifically registered clinical trials, online patient resources, the qualitative literature and landmark studies identified by a study steering committee. 2) The list of outcomes will be scored by multiple stakeholder groups in a two round online international Delphi survey. 3) The results of the online Delphi will be summarised and discussed at a face to face consensus meeting with representation from all stakeholder groups.

**Discussion:** The SCORE-IT study aims to develop an internationally relevant set of core outcomes for use in future trials of glucose lowering interventions for type 2 diabetes. The use of a COS will improve the consistency of outcomes allowing results of studies to be compared and combined and for new effective treatments to made available more quickly.

**Registration:** The core outcome set study, of which this is a part, is registered in the COMET database, [http://www.comet-initiative.org/studies/details/956](http://www.comet-initiative.org/studies/details/956?result=true).

**Keywords**

Core outcome set, systematic review, type 2 diabetes

**Background**

The global prevalence of diabetes was estimated to be 8.8% of adults 20-79 years in 2017 and by 2045 it is predicted that diabetes will affect 623 million people in this age bracket, a 48% increase from 2017, [1] with type 2 diabetes accounting for the majority of cases [2, 3] . Whilst prevention of type 2 diabetes is a key focus for healthcare [4] it is inevitable that a proportion of those considered to be at high risk or “pre-diabetic” will go on to develop type 2 diabetes and require intervention to normalise their blood glucose [5, 6].

Type 2 diabetes is characterised by abnormal glucose metabolism brought about by resistance to insulin action and an inadequate compensatory insulin secretory response [7, 8]. Treatment of type 2 diabetes ultimately aims to control glycaemia, by lifestyle changes or pharmacotherapy, to avoid hyperglycaemia and associated long term complications. Pharmacotherapy for type 2 includes a number of classes of pharmaceutical agents which affect glycaemia through varying cellular mechanisms and resulting physiological actions [9, 10]. Lifestyle changes focus on changes to physical activity and dietary intake with body weight management being the primary focus [11-15]. These may also be supplemented with bariatric surgical intervention [16].

The primary and secondary outcomes used in clinical trials of glucose lowering interventions are varied with systematic reviews identifying inconsistency in the outcomes measured and reported. Although many trials report glycated haemoglobin, other measures of glycaemic control and outcomes relating to hypoglycaemia, mortality, diabetes-related complications and quality of life are less frequently reported. [3-8]. In a recent systematic review of open recruiting trials registered with clinicaltrials.gov no single outcome was measured in 100% of the included studies [17]and this heterogeneity in outcomes may impact on the translatability of trials into benefits for patients. [18, 19].

The relevance and consistency of trial outcomes may be improved by the development of a Core Outcome Set (COS) that represents the minimum set of outcomes that should be measured and reported in any clinical trial for a given condition, in this case type 2 diabetes [13-15].

**Aims and Objective**

The aim of this study is to contribute to the development of an international COS, relevant to glucose lowering interventions for use in studies adults with type 2 diabetes.

The specific study objectives are: to identify a list of outcomes used in current, open clinical trials registered on clinical trials.gov together with outcomes reported in qualitative literature relevant to type 2 diabetes; to prioritise outcomes from the health care professional perspective; to prioritise outcomes from the perspective of patients with type 2 diabetes; to prioritise outcomes from the perspective of researchers in the field and policymakers; and to integrate the outcomes important to all stakeholders into a combined COS.

**Identifying existing knowledge**

A search of the Core Outcome Measures in Effectiveness Trials (COMET) [20] initiative database was completed prior to commencing this project (on 21st October 2016). No published or ongoing COS for trials involving patients with type 2 diabetes without co-morbidity was identified.

# Scope of the core outcome set

This core outcome set will be developed for effectiveness trials evaluating any non-surgical therapeutic intervention for the treatment of hyperglycaemia in adults with type 2 diabetes. Surgical interventions will not be included as these outcomes are captured in an existing COS for bariatric and metabolic surgery [21]. Type 1 diabetes, gestational diabetes, type 2 diabetes in children and maturity onset diabetes of the young (MODY) are outside the scope of this core outcome set.

**Study Oversight**

An international Study Steering Committee (SSC) comprised of three health care professionals, four public contributors and a policy maker with experience of core outcome sets has been established. The remit of the SSC is to oversee the SCORE-IT study, provide feedback on the study protocol and list of outcomes, contribute to the dissemination of the online Delphi survey and to contribute to the final consensus meeting and dissemination of the COS.

**Methods**

The COS development process will involve the steps shown in figure 1. Each of these is described below.

**Step 1 – Identification of outcomes.**

The list of outcomes for use in an online Delphi survey will be generated from the following sources:

1. A systematic review of open and recruiting trials registered with clinical trials.gov. The search strategy and results of this systematic review have been published elsewhere[17].
2. Identification of additional outcomes from long term cardiovascular outcome studies. Guidance released by the Food and Drug Administration (FDA) required clinical trials for the treatment of type 2 diabetes to demonstrate cardiovascular safety of the new treatment by including specific cardiovascular outcomes [22]. The outcomes described by the FDA will be reviewed against the outcomes identified from open, registered trials and new outcomes will be included in the initial list of outcomes for round 1 of the Delphi. Trials initiated in response to the FDA guidance were long term follow up studies that have now been completed or are nearing completion. As most of these studies are no longer recruiting they will not be identified in the clincialtrials.gov search results, instead a list of the key trials that opened between 2008 and 2016 will be provided by the SSC and outcomes extracted.

3. Health talk online is a public website containing information and patient interviews for a range of health conditions. The experiences of patients with type 2 diabetes shared as video clips on health talk online will be reviewed and potential outcomes extracted [23].Only transcripts of patients aged 18 and over without a co-morbidity will be used.

4. Outcomes will be identified from a narrative synthesis of the qualitative literature. The protocol for the narrative synthesis and resulting outcomes has been submitted for publication separately. Briefly a search of the literature in MEDLINE, with no restrictions on date, will be undertaken. The search terms, described in Table 1, comprise empirically tested qualitative methodological filters designed to identify qualitative research from the MEDLINE electronic database with maximum specificity [24]. Abstracts will be screened and the full text will be reviewed for articles meeting the following inclusion criteria: participants are patients with type 2 diabetes, the focus is type 2 diabetes and not an associated co-morbidity, and qualitative methods (interviews and/or focus groups) have been used.

|  |
| --- |
| **Table 1. MEDLINE search strategy** |
| Multi-Field Search |
|  | (type 2 diabetes OR type II diabetes)   | Abstract |
| AND | patient\* | Abstract |
| AND | (Qualitative OR Themes) | Abstract |
| AND | (symptom OR treatment OR living with) | Abstract |
| NOT | (co-morbid\* OR foot ulcer\* OR retinopathy OR nephropathy OR bariatric surgery OR non-alcoholic fatty liver disease OR cardiovascular disease) | Abstract |

5. A recent study by Reaney et al has examined patient reported outcome measures (PROMS) used in phase 3 clinical trials of GLP-1 receptor agonists, novel insulins, SGLT-2 inhibitors and DPP-4 inhibitors [25]. The outcome domains in these PROMS will be reviewed against those identified in sources 1-4 for additional outcomes.

6. The Cochrane database of systematic reviews will be searched for “type 2 diabetes” in the title, abstract and keywords. Eligible reviews will be those of glucose lowering interventions for type 2 diabetes. The outcomes used in the included Cochrane reviews will be extracted and compared against the list of outcomes identified in sources 1-4 for additional outcomes.

7. The EUropean Best Information through Regional Outcomes in Diabetes (EUBIROD) project’s BIRO common data set for clinical practice will be reviewed for potentially relevant outcomes that have not been identified from the systematic review or other sources. [26]

**Review of the final outcome list**

The list of outcomes from all sources will be reviewed by NH and JW to group like outcomes together and categorise each outcome according to a 38 item taxonomy [27]. The outcomes list will then be reviewed by members of the SSC to ensure that; outcomes have been grouped appropriately, the outcome description is clear and that there are no duplications within the outcomes. The SSC will also take into consideration the number of outcomes and may request that outcomes be further condensed and combined or that outcomes be removed if measured in a single or small number of studies or if felt to be irrelevant to glucose lowering interventions. This approach will ensure that the number of outcomes to be scored by participants of the online Delphi survey is manageable.

**Step 2- Prioritisation of outcomes**

**Stakeholder Involvement**

Stakeholder groups representing healthcare professionals, people with type 2 diabetes, researchers in the field and policy makers will be invited to participate in the consensus process (two round online Delphi survey and face to face consensus meeting) (table 2).

|  |
| --- |
| **Table 2. Summary of stakeholders** |
| **Key stakeholder group** | **Stakeholder grouping for presentation of round 1 results in round 2 of the Delphi survey** | **Question participants asked to consider in the online Delphi**  |
| People with type 2 diabetes | People with type 2 diabetes and their carers | “What sorts of changes in your diabetes management, symptoms or your day to day life would tell you that a treatment was actually helping you and what would be important in helping you decide if it’s not’” |
| Carers of someone with type 2 diabetes |
| Healthcare professionals treating people with type 2 diabetes:ConsultantsSpecialist nursesDietitiansPharmacistsGeneral practitionersClinical psychologistsPhysical therapistsExercise specialists | Health Care Professionals | “When treating patients with type 2 diabetes, what results of treatment do you consider to be the most important” |
| Researchers in the field of type 2 diabetes | Researchers  | “When treating patients with type 2 diabetes, what results of treatment do you consider to be the most important” |
| Healthcare policy makers (Health Technology Assessment representatives) | Healthcare policy makers |

People with type 2 diabetes may be older with limited access to an online survey. At the time of registration participants will be asked which 10 year age bracket they fall into. The number of participants in each age range will be monitored to ensure representativeness of the population.

We propose to contact potential participants via national and international professional bodies and patient organisations; these may include but are not limited to those described in additional information file 1.

**Step 2 - Online Delphi survey**

A list of outcomes identified from the sources described in step 1 will be prioritised in a two round online Delphi survey. The Delphi method allows anonymous review and scoring of outcomes in a way that gives equal influence to all who participate, avoids an individual participant being overtly influenced by the opinions of any other participant, facilitates international contribution and, as there is no direct contact between participants, provides a mechanism for reconciling different opinions [28-30].

Outcomes will be categorised using the outcomes taxonomy developed by Dodd *et al*[27]. The outcomes list will be presented grouped into the core areas of death, physiological or clinical, life impact, resource use or adverse events and ordered within these domains according to the 38 categories within the taxonomy.

Participants of the Delphi will be asked to score each outcome using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) nine point Likert scale [31]. In the Delphi process the scale will be presented in the format 1 to 9, with 1 to 3 labelled ‘not important’, 4 to 6 labelled ‘important but not critical’ and 7 to 9 labelled ‘critical’. An option of “unable to score” will also be included together with an option to add a comment to each outcome. All outcomes will be written in plain language and descriptions used reviewed and contributed to by members of the SSC, including public contributors, and the same description used for all stakeholders. Participants may also add any additional outcomes they think important but not already included on the list. Any additional outcomes suggested will be reviewed by two members of the study team and new outcomes agreed by the SSC.

In the second round of the online Delphi survey responses for each stakeholder group will be summarised for each outcome and displayed graphically as the percentage of each stakeholder group who have given each score. All outcomes scored in round 1 will be carried forward to round 2. Participants will be able to view the grouped responses together with their own score in round 1 and will be asked to re-score the outcome based on this information using the same 1-9 scale. Participants may choose to change their score or to keep it the same. New outcomes identified from free text responses in round 1 will be presented in round 2 alongside the verbatim text that led to the outcome. Participants will be asked to score these new outcomes without reflection. Round 2 responses will be analysed using descriptive statistics and summarised according to a predefined definition of consensus (table 3)

All rounds of the Delphi will be delivered online using bespoke web based Delphi software (DelphiManager) designed, hosted and delivered by the University of Liverpool. Registration for participation in the survey will include specific consent questions, completion of the survey will then be considered to imply informed consent.

**Step 3 - Consensus meeting**

The final step in the consensus process will be a face to face consensus meeting to discuss the results of the online Delphi survey and ratify the core outcome set. The meeting will be chaired by an independent facilitator. Participants of the Delphi completing both rounds and who express an interest in attending will be randomly selected to attend to ensure that there are similar numbers from each stakeholder group. Results of the two round Delphi will be presented as outcomes meeting the definition of consensus (table 3) [28]. Where outcomes have reached consensus in or consensus out during the Delphi, participants will have the opportunity to voice opinion should they disagree with inclusion/exclusion of the outcome in the outcome set. Participants raising an objection will be invited to provide further information before all participants of the consensus meeting re-score the outcome. Where outcomes have not reached consensus during the Delphi they will be discussed and participants of the consensus meeting invited to re-score the outcome.

|  |
| --- |
| **Table 3. Definition of consensus** |
| **Consensus Classification** | **Description** | **Definition** |
| **Consensus in** | Consensus that outcome should be included in the core outcome set | 70% or more participants scoring as 7-9 AND <15% participants scoring as 1-3 |
| **Consensus out** | Consensus that outcome should not be included in the core outcomes set | 50% or fewer participants scoring 7-9 in each stakeholder group. |
| **No consensus** |  Uncertainty about importance of outcome | Anything else |

**Ethical considerations**

The COS process will generate generalisable findings that can be extrapolated from the present study to a broader population and therefore ethical approval has been sought from the University of Liverpool Ethics Committee prior to undertaking the consensus methods (online Delphi and consensus meeting) ref: 3306.

**Discussion**

There is currently no published core outcome set for type 2 diabetes. The development of a core outcome set in this clinical area aims to improve the interpretation and comparison of future studies and reduce the risk of outcome reporting bias and heterogeneity across studies. The SCORE-IT study will involve multiple key stakeholder groups to ensure that core outcome set is suitable and well accepted in future research.

**Study Status**

The SCORE-IT study is ongoing with the consensus meeting expected to be completed December 2018.

**Abbreviations**

COMET: Core Outcome Measures in Effectiveness Trials

COS: Core outcome set

DPP-4: Dipeptidyl peptidase-4

FDA: Food and Drug Administration

GLP-1 : Glucagon-like peptide 1

GRADE: Grading of Recommendations Assessment, Development and Evaluation

ICHOM: International Consortium for Health Outcomes Measurement

MODY: Maturity Onset Diabetes of the Young

SGLT 2: Sodium-glucose co-transporter 2

SSC: Study Steering Committee

**Ethical Approval and Consent to participate**

Ethical approval for consensus methods has been obtained from the University of Liverpool Health and Life Sciences Research Ethics Committee (Human participants, tissues and databases) (ref: 3306). All participants of the consensus process provide online proportional consent prior to undertaking the online survey.

**Consent for publication**

Not applicable

**Availability of supporting data**

Not applicable

### Competing interests

PRW is member of the COMET Management Group and co-applicant on grants to support COMET and related work.

JW has received lecture fees from AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, Orexigen & Sanofi; and consultancy (Institutional) from AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Napp, Novo Nordisk and Orexigen; grants to institution from Takeda, Novo Nordisk and AstraZeneca.

**Funding**

This work has received funding from the European Union's Horizon 2020 research and innovation programme (CORBEL, under grant agreement n° 654248)

**Author contributions**

PRW and NLH conceived and designed the study. NLH drafted the manuscript; all authors reviewed and approved the final manuscript. All authors contributed to review of the study design.

Collaborating authors, part of the SCORE-IT Study Team: Serena Battaglia, Jacques Demotes-Mainard, Valerie Gailus-Durner, Silvio Garattini, Cecilia AC Prinsen, Michael Raess, Patricia da Silva-Buttkus, Caroline B Terwee,

Acknowledgements

Not applicable

Author’s information

Not applicable

References

1. **Diabetes Atlas (Eighth Edition)** [<http://www.diabetesatlas.org/resources/2017-atlas.html>]

2. Holman N, Young B, Gadsby R: **Current prevalence of Type 1 and Type 2 diabetes in adults and children in the UK.** *Diabetic Medicine* 2015, **32:**1119-1120.

3. Bruno G, Runzo C, Cavallo-Perin P, Merletti F, Rivetti M, Pinach S, Novelli G, Trovati M, Cerutti F, Pagano G: **Incidence of Type 1 and Type 2 Diabetes in Adults Aged 30–49 Years.** *The population-based registry in the province of Turin, Italy* 2005, **28:**2613-2619.

4. Service NH: **Healthier You: The NHS Diabetes Prevention Programme: NHS Diabetes Prevention Programme Impact Analysis.** vol. Publications Gateway ref: 05529; 2016.

5. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M: **Prediabetes: A high-risk state for developing diabetes.** *Lancet* 2012, **379:**2279-2290.

6. Morris DH, Khunti K, Achana F, Srinivasan B, Gray LJ, Davies MJ, Webb D: **Progression rates from HbA1c 6.0–6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis.** *Diabetologia* 2013, **56:**1489-1493.

7. Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R: **The Natural History of Progression From Normal Glucose Tolerance to Type 2 Diabetes in the Baltimore Longitudinal Study of Aging.** *Diabetes* 2003, **52:**1475-1484.

8. American Diabetes A: **Diagnosis and Classification of Diabetes Mellitus.** *Diabetes Care* 2010, **33:**S62-S69.

9. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: **Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach.** *Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)* 2012, **35:**1364-1379.

10. **2. Classification and Diagnosis of Diabetes.** *Diabetes Care* 2017, **40:**S11-S24.

11. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, Clark NG: **Weight Management Through Lifestyle Modification for the Prevention and Management of Type 2 Diabetes: Rationale and Strategies.** *A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition* 2004, **27:**2067-2073.

12. Wilding JPH: **The importance of weight management in type 2 diabetes mellitus.** *International Journal of Clinical Practice* 2014, **68:**682-691.

13. Wilding JPH: **Medication use for the treatment of diabetes in obese individuals.** *Diabetologia* 2018, **61:**265-272.

14. Anderson JW, Kendall CWC, Jenkins DJA: **Importance of weight management in Type 2 diabetes: Review with meta-analysis of clinical studies.** *Journal of the American College of Nutrition* 2003, **22:**331-339.

15. Bain SC, Feher M, Russell-Jones D, Khunti K: **Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK.** *Diabetes Obes Metab* 2016, **18:**1157-1166.

16. **Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2018.** *Diabetes Care* 2018, **41:**S65-S72.

17. Harman NL, James R, Wilding J, Williamson PR: **SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials.** *Trials* 2017, **18:**597.

18. Heneghan C, Goldacre B, Mahtani KR: **Why clinical trial outcomes fail to translate into benefits for patients.** *Trials* 2017, **18:**122.

19. Tunis SR, Clarke M, Gorst SL, Gargon E, Blazeby JM, Altman DG, Williamson PR: **Improving the relevance and consistency of outcomes in comparative effectiveness research.** *J Comp Eff Res* 2016, **5:**193-205.

20. [<http://www.comet-initiative.org/>]

21. Coulman KD, Hopkins J, Brookes ST, Chalmers K, Main B, Owen-Smith A, Andrews RC, Byrne J, Donovan JL, Mazza G, et al: **A Core Outcome Set for the Benefits and Adverse Events of Bariatric and Metabolic Surgery: The BARIACT Project.** *PLOS Medicine* 2016, **13:**e1002187.

22. Administration FaD: **Guidance for Industry. Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes.**

23. **Health Talk Online** [<http://www.healthtalk.org/peoples-experiences/long-term-conditions/diabetes-type-2/peoples-profiles/aged-35-and-under>]

24. Wong SS, Wilczynski NL, Haynes RB: **Developing optimal search strategies for detecting clinically relevant qualitative studies in MEDLINE.** *Stud Health Technol Inform* 2004, **107:**311-316.

25. Reaney M, Elash CA, Litcher-Kelly L: **Patient Reported Outcomes (PROs) used in recent Phase 3 trials for Type 2 Diabetes: A review of concepts assessed by these PROs and factors to consider when choosing a PRO for future trials.** *Diabetes Research and Clinical Practice* 2016, **116:**54-67.

26. **EUropean Best Information through Regional Outcomes in Diabetes (EUBIROD)** [<http://www.eubirod.eu/biroDataStandards.htm>]

27. Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR: **A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery.** *Journal of Clinical Epidemiology* 2018, **96:**84-92.

28. Sinha IP, Smyth RL, Williamson PR: **Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies.** *PLoS Med* 2011, **8:**e1000393.

29. Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, Clarke M, Gargon E, Gorst S, Harman N, et al: **The COMET Handbook: version 1.0.** *Trials* 2017, **18:**280.

30. Jones J, Hunter D: **Consensus methods for medical and health services research.** *Bmj* 1995, **311:**376-380.

31. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, Alderson P, Glasziou P, Falck-Ytter Y, Schunemann HJ: **GRADE guidelines: 2. Framing the question and deciding on important outcomes.** *J Clin Epidemiol* 2011, **64:**395-400.

**Figures:**

Figure 1. Overview of COS development process.